November 16, 2023
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
November 15, 2023
High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia
Indonesia, Kyrgyzstan, Philippines, Ukraine, Uzbekistan, and Vietnam presented results of LIFT-TB operational research program at the Union Conference on Lung Health; Philippines study yields additional insights on MDR-TB treatment
November 13, 2023
TB Alliance Applauds Macleods’ Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen
Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines
November 9, 2023
New Drug-Resistant TB Treatments Reach Patients in Pakistan as Association for Social Development Accelerates Pilot Implementation
Preliminary results show increased cure rates for hard-to-treat TB infections; leads to update in Pakistan’s treatment guidelines
November 7, 2023
New WHO Global TB Report Shows Recovery in Effort to Combat TB, But Stronger Investments are Needed to Help Reach UN Goals
Statement from Mel Spigelman, M.D., President and Chief Executive Officer, TB Alliance
September 29, 2023
World Leaders Cite the Benefit and Importance of New, Six-Month Drug-Resistant TB Treatment at United Nations High-Level Meeting on Tuberculosis
Member States Commit to Increased Investment in TB Research and to Ensure New Innovations Reach Those in Need
September 22, 2023
UN Commitment on Tuberculosis Needs Leadership to Match Ambition
Statement from Mel Spigelman, MD, President and CEO of TB Alliance
September 15, 2023
Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
Interim results of operational research in LIFT-TB countries support decision to adopt improved treatment
August 14, 2023
Realizing our “Triple-A Mandate”
TB Alliance is committed to ensuring its products are adopted, available and affordable; here’s how we’ve been working to live up to that promise with our six-month DR-TB cure
August 10, 2023